UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ____________________________________________ ...

Xencor, Inc. (NASDAQ:XNCR) Q4 2023 Earnings Conference Call February 27, 2024 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications & Investor Relations Bassil Dahiyat - President & Chief Executive Officer Nancy Valente - Chief Development Officer Dane Leone - Senior Vice President, Corporate Strategy Conference Call Participants Dylan Drakes - Leerink Partners Etzer Darout - BMO Capital Markets Kaveri Pohlman - BTIG Brian Cheng - JPMorgan Tara Bancroft - TD Cowen Operator Good afte ...

Exhibit 99.1 -- Vudalimab (PD-1 x CTLA-4) monotherapy generally well tolerated with encouraging clinical benefit for patients with high-risk mCRPC who have advanced beyond standard of care therapy -- -- Management to Host Conference Call at 4:30 p.m. ET Today -- PASADENA, Calif.--Feb. 27, 2024-- Xencor, Inc. (NASDAQ:XNCR), a clinical-stage biopharmaceutical company developing engineered antibodies for the treatment of cancer and other serious diseases, today reported financial results for the fourth quarter ...

Xencor, Inc. (NASDAQ:XNCR) Q3 2023 Earnings Conference Call November 7, 2023 4:30 PM ET Company Participants Charles Liles - Head, Corporate Communications and Investor Relations Bassil Dahiyat - President and Chief Executive Officer Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Conference Call Participants Edward Tenthoff - Piper Sandler Dane Leone - RJS Etzer Darout - BMO Capital Markets Alec Stranahan - Bank of America Jerry Gong ...

Table of Contents FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended September 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: 001-36182 Xencor, Inc. UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 ____________________ ...

Xencor, Inc. (NASDAQ:XNCR) Q2 2023 Earnings Conference Call August 3, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications & IR Bassil Dahiyat - Co-Founder and CEO Nancy Valente - Chief Development Officer John Desjarlais - Chief Scientific Officer Conference Call Participants Mara Goldstein - Mizuho Securities Etzer Darout - BMO Capital Markets Edward Tenthoff - Piper Sandler Brian Chang - JPMorgan Alec Stranahan - Bank of America Merrill Lynch Kaveri Pohlman - BTIG C ...

UNITED STATES SECURITIES AND EXCHANGE COMMISSION Table of Contents WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended June 30, 2023 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from ________ to ________ _______________________________________________ Commission file number: ...

Xencor, Inc. (NASDAQ:XNCR) Q1 2023 Earnings Conference Call May 8, 2023 4:30 PM ET Company Participants Charles Liles - Head of Corporate Communications, Investor Relations Bassil Dahiyat - President and Chief Executive Officer Allen Yang - Chief Medical Officer John Desjarlais - Chief Scientific Officer John Kuch - Chief Financial Officer Nancy Valente - Chief Development Officer Conference Call Participants Supawat Thongthip - Mizuho Edward Tenthoff - Piper Sandler Brian Cheng - JPMorgan David Nierengarte ...

Table of Contents UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, D.C. 20549 _______________________________________________ FORM 10-Q (Mark One) x QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2023 or 465 North Halstead Street, Suite 200, Pasadena, CA 91107 (Address of principal executive offices) (Zip Code) (626) 305-5900 (Registrant's telephone number, including area code) Securities registered pursuant to Sec ...

Table of Contents` UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 __________________________________________________________ FORM 10-K __________________________________________________________ (Mark One) x ANNUAL REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the fiscal year ended December 31, 2022 or o TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the transition period from to _________________________ ...